阿立哌唑联合度洛西汀对难治性抑郁的疗效及对血管内皮生长因子的作用研究

doi:10.12092/j.issn.1009-2501.2020.08.013

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (8): 937-942.doi: 10.12092/j.issn.1009-2501.2020.08.013

阿立哌唑联合度洛西汀对难治性抑郁的疗效及对血管内皮生长因子的作用研究

杨世涛^1,2，祝一虹^1,3，唐文新⁴

¹浙江大学医学院，杭州 310058，浙江；²建德市第四人民医院，建德 311612，浙江；³浙江大学心理健康教育与咨询中心，杭州 310058，浙江；⁴杭州市第七人民医院，杭州 310013，浙江

收稿日期:2020-05-06 修回日期:2020-07-16 出版日期:2020-08-26 发布日期:2020-09-03
通讯作者: 祝一虹，女，博士，副教授，研究方向：医学心理学、神经心理学。 E-mail: zhuyihong@zju.edu.cn
作者简介:杨世涛，男，本科，副主任医师，研究方向：精神病学。 E-mail: yangstjd@163.com
基金资助:
浙江省公益技术研究计划（LGF19H090015）

Effects of aripiprazole combined with duloxetine on the treatment effect and VEGF level in patients with refractory depression

YANG Shitao ^1,2, ZHU Yihong ^1,3, TANG Wenxin ⁴

¹Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, China; ² The Fourth People's Hospital of Jiande City, Jiande 311612, Zhejiang, China; ³ Mental Health Education and Counseling Center, Zhejiang University, Hanzhou 310058, Zhejiang, China; ⁴ the Seventh People's Hospital of Hangzhou, Hangzhou 310013, Zhejiang, China

Received:2020-05-06 Revised:2020-07-16 Online:2020-08-26 Published:2020-09-03

摘要/Abstract

摘要： 目的：探讨阿立哌唑对度洛西汀治疗难治性抑郁的增效情况及对血管内皮生长因子（VEGF）浓度的影响。方法：选取2017年2月－2019年2月在建德市第四人民医院进行治疗的90例难治性抑郁患者，并招募40例健康志愿者作为健康对照组。通过随机数字表法将患者分为阿立哌唑联合度洛西汀治疗组（联合治疗组）和度洛西汀治疗组（单药治疗组），经过4周治疗后分别评估两组患者之间疗效、不良反应的差异。对比两个治疗组用药前后及与健康对照组之间VEGF水平差异。结果：联合治疗组有效率为88.8%，单药治疗组有效率为80.0%，两组有效率比较差异无统计学意义（P>0.05），治疗4周后联合治疗组汉密顿抑郁量表（HAMD）评分低于单药治疗组，差异有统计学意义（P<0.05），两组不良反应比较差异无统计学意义（R=0.641, P=0.624）。两个治疗组用药前VEGF水平均高于健康对照组，差异有统计学意义（P<0.01），治疗后两组VEGF水平较治疗前下降，差异有统计学意义（P<0.01），联合治疗组VEGF水平低于单药治疗组，差异有统计学意义（P<0.05）。Pearson相关分析显示，治疗前VEGF水平与HAMD评分呈正相关（R=0.403，P<0.01），治疗前后VEGF下降水平与HAMD减分率呈正相关（R=0.330，P<0.01）。结论：阿立哌唑联合度洛西汀较单用度洛西汀对难治性抑郁症有更好的疗效，并可以显著降低外周血中VEGF水平。

关键词: 难治性抑郁, 阿立哌唑, 度洛西汀, 血管内皮生长因子

Abstract: AIM: To explore the effects of aripiprazole and duloxetine on refractory depression and the change of VEGF concentration during treatment. METHODS: Ninety patients with refractory depression who were treated at the Fourth People's Hospital of Jiande from February 2017 to February 2019 were selected, and 40 healthy volunteers were recruited as healthy control groups. Random numbers table was used to divide patients into aripiprazole combined with duloxetine treatment group (combined treatment group) and duloxetine treatment group (monotherapy group). After 4 weeks of treatment, the differences in efficacy and adverse reactions between the two groups were evaluated. The difference of VEGF level between each group was compared. RESULTS: The effective rate was 88.8% in the combined treatment group and 80.0% in the monotherapy group. The effective rate between the two groups was not statistically significant (P<0.05). After 4 weeks of treatment, the HAMD score in the combined treatment group was lower than that in the monotherapy group, the difference was statistically significant (P<0.05). The difference in adverse reactions between the two groups was not statistically significant (R=0.641, P=0.624). The level of VEGF before treatment in the two treatment groups was higher than that in the healthy control group, and the difference was statistically significant (P<0.01). After treatment, the VEGF level of the two groups decreased compared with before treatment, and the difference was statistically significant (P<0.01). The level of VEGF in the combined treatment group was lower than that in the monotherapy group, and the difference was statistically significant (P<0.05). Pearson correlation analysis showed that the level of VEGF before treatment was positively correlated with the HAMD score (R=0.403, P<0.01), and VEGF decline level is positively correlated with HAMD score reduction rate (R=0.330, P<0.01). CONCLUSION: Aripiprazole combined with duloxetine has a better effect on refractory depression than duloxetine alone, and can significantly reduce the level of VEGF in peripheral blood.

Key words: refractory depression, aripiprazole, duloxetine, vascular endothelial growth factor

中图分类号:

R749

杨世涛, 祝一虹, 唐文新. 阿立哌唑联合度洛西汀对难治性抑郁的疗效及对血管内皮生长因子的作用研究[J]. 中国临床药理学与治疗学, 2020, 25(8): 937-942.

YANG Shitao, ZHU Yihong, TANG Wenxin. Effects of aripiprazole combined with duloxetine on the treatment effect and VEGF level in patients with refractory depression[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 937-942.

[1]	卢锐斌, 赵辉, 谢秋玲, 胡露, 郭朝万, 裴运林, 熊盛. 抗FGF-2纳米抗体抑制碱烧伤诱导大鼠角膜血管新生[J]. 中国临床药理学与治疗学, 2021, 26(6): 609-615.
[2]	陈连洲，李松华，蒲犇. 阿立哌唑联合草酸艾司西酞普兰对重度抑郁患者多巴胺、5-羟色胺和皮质醇的影响研究[J]. 中国临床药理学与治疗学, 2019, 24(4): 446-450.
[3]	张皇，全婵娟，杨新怀，黄淑兰，高松哲，王肖，陈荣，陈岚. 康柏西普联合玻璃体切割术对糖尿病性黄斑水肿患者房水VEGF、SDF-1的影响[J]. 中国临床药理学与治疗学, 2019, 24(2): 218-222.
[4]	景钦东，刘海鹏，王斌儒，陈康，陈晓. 甲磺酸阿帕替尼治疗进展期胃癌的研究进展[J]. 中国临床药理学与治疗学, 2019, 24(10): 1194-1200.
[5]	曹林忠，汪小敏，张虎林，郭成龙，苏亮磊，刘新宇. 生骨再造丸对兔激素性股骨头坏死VEGF及FLT-1表达的影响[J]. 中国临床药理学与治疗学, 2018, 23(8): 874-880.
[6]	李敏江，陈栋，陈文斌. β-肾上腺素能受体阻滞剂和COX-2抑制剂在结直肠癌肝转移中的作用研究[J]. 中国临床药理学与治疗学, 2018, 23(8): 893-899.
[7]	李晓洁，张胜威，王华胜，王东，梅家转，邓业巍. VEGF-A基因多态性对接受氟尿嘧啶为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2018, 23(8): 900-904.
[8]	罗勇，李崎，华特波. 新辅助化疗联合乳腺癌改良根治术对乳腺癌患者免疫功能、基质金属蛋白酶及血管内皮生长因子的影响[J]. 中国临床药理学与治疗学, 2018, 23(1): 104-109.
[9]	杨红，林杉，杨宏，谢晓薇，王新. 艾拉莫德对类风湿关节炎患者血管内皮生长因子及色素上皮衍生因子表达的影响[J]. 中国临床药理学与治疗学, 2017, 22(1): 68-71.
[10]	陶绍能，王莹莹，戴云海，程光华，吕坤. 体外沉默血管内皮生长因子对D-(-)-MTX/A549耐药细胞株迁移侵袭能力的影响[J]. 中国临床药理学与治疗学, 2016, 21(7): 745-748.
[11]	吴义高，施星明，江芹，储照虎. 度洛西汀联合巴戟天寡糖胶囊治疗卒中后抑郁的临床研究[J]. 中国临床药理学与治疗学, 2016, 21(7): 816-820.
[12]	杨艳，夏泳，朱长江，陈艳波. 阿立哌唑对氨磺必利所致高泌乳素血症的影响研究[J]. 中国临床药理学与治疗学, 2016, 21(6): 693-696.
[13]	徐涛，金法，李宁，叶志鹏，吴可人，李志杰. 分化相关基因-1在血管损伤后新生内膜形成中的表达及临床意义[J]. 中国临床药理学与治疗学, 2016, 21(10): 1108-1113.
[14]	陈淑慧, 阳帆帆, 何君, 周鹏, 王桂华. 胃癌靶向治疗研究最新进展[J]. 中国临床药理学与治疗学, 2015, 20(8): 950-955.
[15]	林国芳. 姜黄素对大鼠局灶性脑缺血再灌注血管内皮生长因子和水通道蛋白4的影响[J]. 中国临床药理学与治疗学, 2015, 20(6): 621-624.

阿立哌唑联合度洛西汀对难治性抑郁的疗效及对血管内皮生长因子的作用研究

Effects of aripiprazole combined with duloxetine on the treatment effect and VEGF level in patients with refractory depression

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价